Tyrosine kinase inhibitorFDA-approvedSecond-line
Ribociclib
How it works
Blocks the CDK4/6 enzymes that drive cell division in cancer cells, allowing the body's natural repair mechanisms to take over.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Clinical trials have demonstrated that ribociclib can improve progression-free survival and overall survival in patients with hormone receptor-positive breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Ribociclib and Hormone Therapy in Early Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing Letrozole and Ribociclib in Early Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ribociclib and Letrozole Effective in Older Women with Advanced Breast Cancer | Breast Cancer | preclinical | The median progression-free survival was 36 months, and the breast cancer-specific survival rate at 24 and 36 months was 82% and 75%, respectively. | Source → |
| Combining Ferulic Acid with Breast Cancer Drugs May Improve Treatment | Breast Cancer | lab-study | — | Source → |
| New Nanoparticle Delivery System for Breast Cancer Treatment | Breast Cancer | lab-study | The RIB-LNC exhibited a 1.31-fold and 3.09-fold reduction in IC values in MDA-MB-231 and MCF-7 cells, respectively, as compared to free RIB. | Source → |
| New Treatment Combination Approved for High-Risk Breast Cancer | Breast Cancer | phase-3 | The invasive disease-free survival at 36 months was 90.7% for Ribo + AI versus 87.6% for AI, with a hazard ratio of 0.75. | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.